Symposium participants received a comprehensive review of cellular medicine, review current techniques, and learn various applications and protocols for delivering stem cell treatments to patients that address a range of health and aesthetic indications. The field of regenerative medicine is expanding at an exponential rate. The number of clinical trials employing adult stem cells is now in the thousands.
EVENT / what it’s all about
SPEAKERS / meet the experts
AGENDA / event schedule
Dr. Fernando Espina Otero
08:00 - 09:00
KEYNOTE SPEECH AND OPENING REMARKS
Dr. Enrique Testart
09:00 - 10:00
USE OF MSC TO ENGINEER DEVELOPMENTAL PROCESSES FOR REGENERATIVE MEDICINE
Following the exemplifying context of cartilage and bone regeneration, this lecture will describe and discuss alternative approaches to evolve classical tissue engineering paradigms towards possibly more effective grafts, with the potential for a broader clinical use.
The lecture will then propose and discuss the concept of engineering regenerative strategies by recapitulating developmental processes, exploiting the own body as the in vivo bioreactor. Rather than engineering a tissue, the strategy targets the use of cells (e.g., MSC) to engineer the different stages of a process which recapitulate events of development (e.g., endochondral ossification).
The product will be a tissue containing all necessary and sufficient cues to remodel into the target repair tissue upon grafting. The perspective will also address issues related to scalability, process control and regulatory compliance in manufacturing cell-based products and highlight the need not only to automate, but also to streamline and simplify typical production processes.
Dr. Joseph Purita
10:00 - 11:00
BONE NATURE AND BLOOD NURTURE: SAME STROMA?
Contrasting the relatively well known hierarchy and roles of haematopoietic cells in the bone marrow, lineage and functional relationships among non-hematopoietic cells have remained elusive, despite the large interest raised by their haematopoietic and immune regulatory properties. Among other cell types, endothelial cells, neuroglial cells, mesenchymal progenitors and osteochondral cells have been proposed as key elements of the haematopoietic stem cell (HSC) niche in the bone marrow. However, the developmental and functional relationships of these cells have remained poorly characterised. Technological developments have allowed start dissecting them but have also evidenced limitations that need to be overcome in order to advance the field.
We previously showed that bone marrow nestin+ cells innervated by sympathetic nerve fibers regulate normal haematopoietic stem cells. Our recent data has demonstrated that this circuitry is critically damaged in myeloproliferative neoplasms, diseases that were previously thought autonomously driven by mutated haematopoietic stem cells. We will discuss origins and functions of bone marrow mesenchymal stem cells (MSCs) and the potential therapeutic implications.
CEO Agencia Sanitaria Privada InHouse
11:00 - 12:00
MSC BASED THERAPY FOR SEVERE OSTEOARTHRITIS OF THE KNEE: THE ADIPOSE EXPERIENCE
Identify specific signature associated with MSC immunosupressive effects, Potency assay associated with osteoarticular applications: where do we stand, MSC for osteoarthritis. implication of IL1RA expression.
Dr. Carlos Guerrero Silva
12:00 - 13:00
MESENCHYMAL STEM CELL TRANSPLANTATION TO TREAT MULTIPLE SCLEROSIS
Mesenchymal stem cells (MSCs) have potent immunomodulatory, tissue-protective, and repair-promoting properties in vitro and in animal models. Clinical trials support the safety and efficacy of MSC transplantation in several human conditions. Published experience in multiple sclerosis (MS) is modest.
We recently completed a phase 1 study of autologous MSC transplantation in MS. 1-2×106 culture-expanded, bone-marrow-derived MSCs/kg were administered IV to 16 women and 8 men, 10 relapsing-remitting and 14 secondary progressive, mean age 46.5 and EDSS 5.2, and 25% with Gd-enhancing brain lesions. Mean cell dosage (requiring 1-3 passages) was 1.9×106 MSCs/ kg (range 1.3-2.0) with post-thaw viability >95%. Cell infusion was well tolerated.
There were no treatment-related severe or serious adverse events, or indication of disease activation. Trend analysis using splines suggested benefit in a number of exploratory clinical, imaging, and laboratory assessments, which will help guide planned phase 2 testing
Dr. Alejandro Guiloff
13:00 - 14:00
STEM CELLS IMMUNOLOGY AND PATHOLOGICAL AND THERAPEUTIC IMPLICATIONS
Mesenchymal stem cells (MSCs) are specifically attracted to damaged tissue sites and are believed to closely interact with inflammatory factors and cells during tissue repair and regeneration., MSCs play a key role in regulating immune responses.
The immune regulatory capacity of MSCs is plastic and varies according to the type and intensity of inflammation. Exogenously administered MSCs are believed to promoted tissue regeneration mainly through inflammation-induced cell empowerment.
Rodrigo Arancibia PhD
CEO, Cellus Medicina Regenerativa S.A
14:00 - 15:00
BRINGING MESENCHYMAL STEM CELLS INTO THE CLINIC
Mesenchymal Stromal Cells (MSCs) have immunemodulatory properties. MSCs have been infused intravenously, no acute infusional toxicity has been reported. Upon contact with blood, MSCs initiate activation of the complement and coagulation cascades.